Table 5. Outcomes in our study and four recent landmark clinical trials that examined the effect of chemo-immunotherapy in ES-SCLC patients.
| Outcome | Chemo-immunotherapy with TRT (our study) | Chemo-immunotherapy alone | |||
|---|---|---|---|---|---|
| IMpower133 (5) | CASPIAN (6) | KEYNOTE-604 (8) | ASTRUM-005 (9) | ||
| mOS, months | 20.0 | 12.3 | 12.9 | – | 15.4 |
| mPFS, months | 9.2 | 5.2 | 5.1 | 4.8 | 5.8 |
| mlPFS, months | 14.9 | – | – | – | – |
| mdPFS, months | 10.8 | – | – | – | – |
| ORR, % | 59.0 | 60.2 | 67.9 | 70.6 | 68.9 |
| DCR, % | 89.8 | 81.1 | – | 88.1 | 93.1 |
ES-SCLC, extensive-stage small cell lung cancer; TRT, thoracic radiotherapy; mOS, median overall survival; mPFS, median progression-free survival; mlPFS, median local progression-free survival; mdPFS, median distant progression-free survival; ORR, objective response rate; DCR, disease control rate.